Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Dyne Therapeutics Inc
(NQ:
DYN
)
31.94
-14.15 (-30.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
13,729,622
Open
27.77
Bid (Size)
32.52 (4)
Ask (Size)
32.95 (1)
Prev. Close
46.09
Today's Range
23.55 - 33.61
52wk Range
6.400 - 47.45
Shares Outstanding
58,310,703
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
Today 14:59 EDT
Via
Benzinga
Exposures
Fossil Fuels
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Today 13:41 EDT
Via
Benzinga
Performance
YTD
+144.56%
+144.56%
1 Month
-22.49%
-22.49%
3 Month
+1.69%
+1.69%
6 Month
+23.46%
+23.46%
1 Year
+173.93%
+173.93%
More News
Read More
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Today 12:37 EDT
Via
Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
Today 12:04 EDT
Via
Investor's Business Daily
Nasdaq Dips Over 2%; US Construction Spending Falls In July
Today 12:00 EDT
Via
Benzinga
Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates
Today 10:19 EDT
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Today 8:03 EDT
Via
Benzinga
Dyne Therapeutics Announces Key Leadership Appointments
Today 6:31 EDT
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
Today 6:30 EDT
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?
August 21, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?
August 13, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024
August 12, 2024
Via
InvestorPlace
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 12, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
Via
Benzinga
Chart Of The Day: Dyne Therapeutics - Deeply Discounted
July 10, 2024
Via
Talk Markets
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
June 24, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 13, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
June 12, 2024
Via
Benzinga
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
June 12, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
June 04, 2024
Via
InvestorPlace
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
May 28, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
May 21, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.